immunitoAI

The model is the product. AbInitio generates antibody sequences with chosen drug characteristics against a named target, and the company calls intelligence the foundation it is built on. The laboratory exists to check what the model produces. Remove the model and there is no product, which is the whole premise of a company that designs antibodies rather than screening for them.

immunitoAI generates antibody sequences and validates them in its own lab, so there is a check on what the model produces. The rules around that check are not described: where a person reviews or overrides a design, what follows when validation fails, and which steps run without a human. The validation is named as a step without the governing rules that would make it a control.

The platform is named and described only in general terms. AbInitio is called a foundational AI built entirely in house, which conveys that the company owns its model without naming it, giving an architecture or parameter count, or characterizing the training data. No version or update practice is published.

The model is presented as built entirely in house, and no outside model provider is named. Beyond that nothing is established: no compute or hosting provider is named, no third party components are listed, there is no subprocessor list, and nothing describes what governs a target once it enters the system.

The evidence is a claim rather than a result a reader can check. immunitoAI says it produces biologically viable sequences in weeks and validates them in house, and it has raised a Series A to build a pipeline, but it names no customer, no partner with money committed, no clinical program and no outcome figures, and publishes no peer reviewed work. Funding is the firmest public signal, and funding is not evidence that a design worked.

The inputs are target and antibody data rather than patient records, so no protected health information is at stake. How a customer's or partner's target is handled once it reaches the platform, whether retained, used in training, or kept apart from other work, is not something immunitoAI describes.

No business associate status is stated and no privacy document reaching the platform is published. immunitoAI works with antibody and target data rather than patient records, so a HIPAA posture is not expected, and none is stated.

A privacy policy and terms are published, but a security reviewer looking for an independent attestation finds none: no SOC 2 report, ISO 27001 or HITRUST certification, no trust portal, and no security page. Nothing from an outside party speaks to how the environment is secured.

No device claim is made, and the company is scoped to match. immunitoAI designs antibodies at the discovery stage, so any regulatory position belongs to the molecules and whoever develops them. There is no clearance to hold and none is claimed.

immunitoAI's headline claim about AbInitio is speed, biologically viable sequences in weeks. Speed is not a measure of how reliably the model performs, which is what governance turns on, and the company publishes no benchmark, audit or responsible AI policy that would supply it. How often the model is right goes unaddressed.

If a design does not work, immunitoAI says nothing about what comes next. No hit rate or error rate with a method and a denominator is given, so there is no measure to stand on, and no guarantee, indemnity or correction route accompanies a design.

The platform produces antibody designs, not software a buyer integrates, so there is no clinical record surface, as a design company would not have one. No research system of record is named as connected and no connector is offered, so the output stands on its own rather than flowing into a buyer's systems.

The platform runs for immunitoAI rather than being deployed to anyone, so there is no tenancy or hosting model to evaluate. Location is implied by the company's base in India rather than committed, and nothing published names where target and design data rests.

immunitoAI presents a platform and a pipeline without a stated way to buy, a rate card or a unit of charge. A buyer comes away understanding what the company does but with no way to tell how it is sold or what it costs.

Coverage is claimed broadly without specifics. immunitoAI says AbInitio generates antibodies for any protein target, which is a wide claim, but no particular target, disease area or validated program is named to show where that has been demonstrated.